Correspondence
What do we actually know about leprosy worldwide?

https://doi.org/10.1016/S1473-3099(16)30090-1Get rights and content

References (5)

  • CS Smith et al.

    Time to define leprosy elimination as zero leprosy transmission?

    Lancet Infect Dis

    (2016)
  • DJ Blok et al.

    Global elimination of leprosy by 2020: are we on track?

    Parasit Vectors

    (2015)
There are more references available in the full text version of this article.

Cited by (34)

  • Leprosy case series in the emergency room: A warning sign for a challenging diagnosis

    2021, Brazilian Journal of Infectious Diseases
    Citation Excerpt :

    For leprosy surveillance, 15 intra-domiciliary contacts from four leprosy patients were also evaluated, and three (20%) new leprosy patients were diagnosed, all from the same family. The decline in leprosy prevalence and the commitment to leprosy elimination as a public health problem in many countries have been accompanied by a decline in disease expertise.9 Leprosy can mimic many common dermatological and neurological conditions,4,5 leading to delays in diagnosis.

  • Molecular epidemiology of leprosy: An update

    2020, Infection, Genetics and Evolution
    Citation Excerpt :

    Nevertheless, new cases continue to evolve around the world and in 2018, nearly 250,000 new leprosy cases were reported from 131 countries, with 95% of those detected mainly in India, Brazil, Indonesia and 20 other global priority countries (WHO, 2019). Pockets of high endemicity remain even within some countries which have achieved the ‘elimination’ goal, as large numbers of hidden cases are often discovered following local intensive case detection campaigns (Blok et al., 2016; de Sousa et al., 2020; Kumar et al., 2013; Rao and Suneetha, 2018; Salgado et al., 2016, 2018; Smith et al., 2015). Additionally, 7.6% (n=16,013) of the new leprosy cases detected globally still occurs among children (with 96% of all cases in the 23 global priority countries), suggesting there is continuing active transmission of the disease within some communities.

  • IL-37 and leprosy: A novel cytokine involved in the host response to Mycobacterium leprae infection

    2018, Cytokine
    Citation Excerpt :

    Leprosy is a chronic disease of infectious origin caused by Mycobacterium leprae, an intracellular bacillus that causes granulomatous and demyelinating lesions in the peripheral nerves [1,2]. Leprosy still constitutes an important public health problem in some regions of the world, mainly because of its high severity and disabling potential [3–5]. As leprosy is a spectral disease, according to the Ridley and Jopling classification, the disease presents in five clinical forms: two stable forms that constitute the poles of the disease, tuberculoid leprosy (TT) and lepromatous leprosy (LL), and three forms that are considered as intermediary, including borderline tuberculoid (BT), borderline borderline (BB), and borderline lepromatous (BL) [6].

  • Are leprosy case numbers reliable?

    2018, The Lancet Infectious Diseases
  • Salivary anti-PGL-1 IgM may indicate active transmission of Mycobacterium leprae among young people under 16 years of age

    2017, Brazilian Journal of Infectious Diseases
    Citation Excerpt :

    However, this decline has become less steep in recent years; on the contrary, there has been a rise in leprosy cases including children.6 This makes the goal of eliminating leprosy impossible to be achieved in the next few years,2 remembering that there are possible undiagnosed cases that are hidden sources of bacterial transmission. In addition, there are many unknown aspects regarding the ecology of M. leprae.6

View all citing articles on Scopus
View full text